Wave Life Sciences (WVE) to Release Earnings on Thursday

Wave Life Sciences (NASDAQ:WVE - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $11.65 million for the quarter.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.34. The company had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. On average, analysts expect Wave Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Wave Life Sciences Price Performance

WVE traded down $0.44 on Tuesday, reaching $7.29. The company's stock had a trading volume of 320,708 shares, compared to its average volume of 1,244,233. Wave Life Sciences has a 1 year low of $4.25 and a 1 year high of $16.74. The business's 50 day moving average is $8.10 and its 200 day moving average is $11.36. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -6.61 and a beta of -0.91.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on WVE shares. Jefferies Financial Group began coverage on shares of Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 price target for the company. StockNews.com raised shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Wedbush began coverage on shares of Wave Life Sciences in a research note on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Finally, Cantor Fitzgerald assumed coverage on Wave Life Sciences in a research note on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $21.17.

Insider Activity at Wave Life Sciences

In related news, CEO Paul Bolno sold 169,025 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at $3,238,019.07. This trade represents a 33.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christian O. Henry sold 10,500 shares of the business's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the transaction, the director now owns 16,115 shares of the company's stock, valued at $157,443.55. This trade represents a 39.45 % decrease in their position. The disclosure for this sale can be found here. Insiders own 29.10% of the company's stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.